Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Sino Biological Announces Successful Closing of 4.98 Billion RMB Public Offering and Listing on the Shenzhen ChiNext Stock Exchange

Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company which provides biological research reagents and related technical contract research services, announced a successful listing on the Shenzhen Stock Exchange subsidiary ChiNext under the stock abbreviation Sino Biological and stock code 301047.

From Sino Biological Inc. 17 Aug 2021

Biotium releases new ExoBrite EV Membrane Staining Kits

Biotium, a leading supplier and inventor of fluorescent cellular probes for life science research, announces the release of new ExoBrite™ EV Membrane Staining Kits.

17 Aug 2021

New rapid test for understanding immunity against COVID-19

Electronics specialist Mantracourt has helped engineer a new rapid test which will tell people whether they have immunity against coronavirus and whether that immunity comes from developing antibodies after infection or the vaccine.

17 Aug 2021

Making the nanobody big again for Cryo-EM

Researchers describe the method that allows high-resolution structure determination of small proteins by single-particle cryo-EM using a Legobody.

17 Aug 2021

Data reinforces SAB-185’s potential to neutralize SARS-CoV-2 variants

A study, available on the pre-print server bioRxiv*, evaluated the neutralizing capacity of a fully human polyclonal antibody (SAB-185) against the Delta, Kappa, and Lambda variants using a lentiviral-based pseudovirus assay.

17 Aug 2021

In Southeast Asia, robust immunity found up to 9 months after SARS-CoV-2 infection

Now, a new study posted to the bioRxiv* preprint server focuses on functional immune memory to SARS-CoV-2, up to nine months in a Southeast Asian cohort, in the absence of re-infection.

16 Aug 2021

Vaccinating previously infected induces more potent antibodies less susceptible to escape from SARS-CoV-2 variants

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causal agent of the coronavirus disease 2019 (COVID-19) pandemic, which has claimed more than 4.3 million lives worldwide. Even after implementing various measures, such as vaccination and social restrictions, SARS-CoV-2 and its variants of concern (VoC) leave the world's public health systems and economies in turmoil.

16 Aug 2021

Moderna COVID-19 vaccine safe and efficacious in adolescents according to a new study

The safety, immunogenicity, and efficacy of the vaccines in adolescents are largely unknown. Now, a new study published in the New England Journal of Medicine evaluates the safety and efficacy of the mRNA-1273 vaccine in adolescents (12-17 years of age).

16 Aug 2021

Penn researchers reveal complex details of T-cell responses to mRNA COVID-19 vaccines

Messenger-RNA (mRNA) vaccines against the coronavirus that causes COVID-19 provoke a swift and strong response by the immune system's T cells - the heavy armor of the immune system - according to a study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

16 Aug 2021

Obtained SARS-CoV-2 immunity, naturally or via vaccination persists 12 months

In a research paper recently uploaded to the preprint server medRxiv* by Havervall et al. (August 12th, 2021), neutralizing antibody titers towards wild-type SARS-CoV-2 and several variants of concern in individuals having either been vaccinated or infected with mild COVID-19 one year earlier are assessed, finding a reduced neutralization capacity against some strains.

16 Aug 2021

Researchers assess the genetic features of T-cell immunity development to SARS-CoV-2 variants

The continuing emergence of new SARS-CoV-2 mutations allows the virus to spread more effectively and evade antibodies. However, it is unclear whether new strains are capable of evading T-cell immunity - one of the body's main lines of defense against COVID-19.

16 Aug 2021

Primate study shows benefit of mRNA vaccine booster shot against SARS-CoV-2 variants

In a recent bioRxiv* preprint research paper, a large group of US scientists demonstrate how a booster dose of the mRNA-1273 vaccine can substantially improve both the potency and range of neutralizing antibody responses and mediate protection against upper and lower airway infection by a range of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern – even those relatively resistant to in vitro neutralization.

16 Aug 2021

SARS-CoV-2 Spike may trigger production of antibodies that cross-react with human thrombopoietin to induce thrombocytopenia

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected individuals often suffer from thrombocytopenia, a condition associated with low platelet counts. The cytokine thrombopoietin regulates platelet count. Previous studies have reported that thrombocytopenia can increase the coronavirus disease 2019 (COVID-19) mortality rate by about five times.

16 Aug 2021

Certain intestinal bacteria induce cross-reactive IgA responses to the SARS-CoV-2 spike RBD

A new study finds that human gut bacteria can induce antibodies of the immunoglobulin A (IgA) subtype that cross-react with the SARS-CoV-2 spike RBD.

15 Aug 2021

World-first trial of third dose COVID-19 booster vaccine shows improved protection in transplant patients

Scientists with the Ajmera Transplant Centre at UHN have conducted a first-in-the-world randomized placebo-controlled trial of third dose COVID-19 booster vaccine for transplant patients that shows substantially improved protection.

14 Aug 2021

Pfizer CEO to public: Just trust us on the covid booster

Pfizer CEO Albert Bourla was confident in June about the ability of his company's vaccine to protect against the highly contagious delta variant, as it marched across the globe and filled U.S. hospitals with patients.

13 Aug 2021

Discovery of highly potent neutralizing monoclonal antibodies against SARS-CoV-2

A new study published in the journal Nature Communications has reported two neutralizing antibodies, namely, nCoVmab1 and nCoVmab2, which are potent against SARS-CoV-2.

13 Aug 2021

SARS-CoV-2 variants containing L452R spike mutation more resistant to antibody-mediated neutralization

A team of scientists from Frankfurt, Germany, has recently explored the efficacy of vaccine- or infection-induced antibodies and therapeutic monoclonal antibodies in neutralizing kappa and delta variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

12 Aug 2021

Camelid nanobody anti-SARS-CoV-2 drug candidates

In a research paper recently published in the journal eLife, researchers from several US institutions have developed a nanobody-based candidate drug that effectively prevents and suppresses severe SARS-CoV-2 infection in animals.

12 Aug 2021

New research offers hope to increase efficacy of immunotherapy for lung cancer

Lung cancer is the leading cause of cancer-related death. Current treatments employ immunotherapy, often in combination with chemotherapy, but benefits to patients remain slight.

11 Aug 2021

Antibody News and Research

Further Reading

Sino Biological Announces Successful Closing of 4.98 Billion RMB Public Offering and Listing on the Shenzhen ChiNext Stock Exchange

Biotium releases new ExoBrite EV Membrane Staining Kits

New rapid test for understanding immunity against COVID-19

Making the nanobody big again for Cryo-EM

Data reinforces SAB-185’s potential to neutralize SARS-CoV-2 variants

In Southeast Asia, robust immunity found up to 9 months after SARS-CoV-2 infection

Vaccinating previously infected induces more potent antibodies less susceptible to escape from SARS-CoV-2 variants

Moderna COVID-19 vaccine safe and efficacious in adolescents according to a new study

Penn researchers reveal complex details of T-cell responses to mRNA COVID-19 vaccines

Obtained SARS-CoV-2 immunity, naturally or via vaccination persists 12 months

Researchers assess the genetic features of T-cell immunity development to SARS-CoV-2 variants

Primate study shows benefit of mRNA vaccine booster shot against SARS-CoV-2 variants

SARS-CoV-2 Spike may trigger production of antibodies that cross-react with human thrombopoietin to induce thrombocytopenia

Certain intestinal bacteria induce cross-reactive IgA responses to the SARS-CoV-2 spike RBD

World-first trial of third dose COVID-19 booster vaccine shows improved protection in transplant patients

Pfizer CEO to public: Just trust us on the covid booster

Discovery of highly potent neutralizing monoclonal antibodies against SARS-CoV-2

SARS-CoV-2 variants containing L452R spike mutation more resistant to antibody-mediated neutralization

Camelid nanobody anti-SARS-CoV-2 drug candidates

New research offers hope to increase efficacy of immunotherapy for lung cancer

Event guide: 5th Novel Conjugates Summit 2026 eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo